Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS)
This article discussese the effectiveness of Oscillococcinum® in the protection from upper respiratory tract infections in patients with chronic obstructive pulmonary disease who had been vaccinated against influenza infection over the 2018–2019 winter season.